Open main menu

Psychiatrienet β

Moclobemide-agomelatine

Revision as of 11:53, 4 August 2023 by Joost (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from moclobemide to agomelatine.[1] [2]

Nietinrijdenbord.png Stop moclobemide
  • Before day 1: gradually reduce dosage of moclobemide to a maximum of 300 mg/day.
  • Day 1: reduce the dosage of moclobemide to 150 mg/day.
  • Day 8: stop administration of moclobemide.
Eenrichtingbord.png Start agomelatine
  • Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.[3]
  • If necessary, increase dosage of agomelatine to 50 mg/day.
Infobord.png More information
  • Because of short halve life of moclobemide after stopping, the next antidepressant can start next day.
  1. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. ↑ McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Moclobemide-agomelatine&oldid=10002"